GeoVax Labs, Inc. · NASDAQ:GOVX
GeoVax Labs — Investor Presentation (February 2026)
27 slides from GeoVax Labs's investor presentation, February 2026
Slide 1: GeoVax Corporate Overview
GeoVax Corporate Overview February 2026 Nasdaq: GOVX 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstanc
Slide 3: Upcoming Clinical Catalysts
Upcoming Clinical Catalysts Program 2026 milestones GEO-MVA First U.S.-sourced Expedited Development Pivotal Phase 3 trial Path commencing 2H26 Rapid enrollment & U.S.-sourced MVA vaccine against Clinical material successfully trial completion Mpox & Smallpox; will expand global manufactured and rea
Slide 4: Pipeline Addresses Significant Unmet Medical Needs and Large Commercial Opportunities
Pipeline Addresses Significant Unmet Medical Needs and Large Commercial Opportunities Global Product Indication Phase 1 Phase 2 Phase 3 Market Opportunity GEO-MVA Mpox/Smallpox n/a n/a $11B+ GEO- CM04S1 COVID-19 $30B+ Solid tumor Gedeptin® therapy/Head & $15B+ Neck Cancer Global Development & Commer
Slide 5: Value Inflection Timeline
Value Inflection Timeline Year Milestone Value Impact 2025 EMA Expedited Path De-risk regulatory path 2H26 Phase 3 start (GEO-MVA) Binary value inflection 2028-2029 Licensure / procurement First revenue Oncology + COVID 2028–30 Upside optionality partnerships 5
Slide 6: Validated Platforms with Broad Infectious Disease & Oncology Applications
Validated Platforms with Broad Infectious Disease & Oncology Applications VALIDATE & SCALE Regulatory 2027-30 De-risk • Commercial focus Clinical 2023-26 • COVID & oncology Pipeline • Expedited Late- monetization Corporate stage approval • U.S. manufacturing 2021-22 pathway Reset implemented • Multi
Slide 7: GeoVax is Implementing a Business Strategy Against a Broad Range of Cancers & Infectious Diseases
GeoVax is Implementing a Business Strategy Against a Broad Range of Cancers & Infectious Diseases Innovate Differentiate Accelerate Collaborate Unique, patented products addressing unmet medical needs Targeting populations unserved/underserved by existing products/standard of care Pursuing expedited
Slide 8: Scalable MVA Platform for Infectious Disease Commercialization
Scalable MVA Platform for Infectious Disease Commercialization MVA Platform Advantages Why MVA Historically Breakthrough: Commercial (Infectious Diseases) Failed to Scale Scale Manufacturing • Excellent safety profile; non- • Reliance on chicken embryo • Continuous avian cell-line replicating in hum
Slide 9: GeoVax Investment Thesis
GeoVax Investment Thesis • Near-term regulatory catalysts • Structural monopoly break • Single global MVA supplier → U.S. sovereign alternative • National Security Asset: Only U.S.-based, scalable MVA manufacturing platform addressing a recognized biodefense and pandemic preparedness gap • De-risked
Slide 10: Capital Strategy
Capital Strategy Non-dilutive funding (BARDA, HHS, DoD, CEPI) Strategic partnerships Reduced equity-sourced capital needs post-Phase 3 (GEO-MVA) de-risking 10
Slide 11: Corporate
Corporate 11
Slide 12: Leadership with Proven Results in Driving Shareholder Value
Leadership with Proven Results in Driving Shareholder Value David Dodd Kelly McKee, MD, MPH Mark Newman, PhD Mark Reynolds Chairman & CEO Chief Medical Officer Chief Scientific Officer Chief Financial Officer Senthil Ranganathan, PhD John Sharkey, PhD Susan Hensley, MS, RAC TomTom O’Brien O’Brien VP
Slide 13: Upcoming Clinical Catalysts
Upcoming Clinical Catalysts Program 2026 milestones GEO-MVA First U.S.-sourced Expedited Development Pivotal Phase 3 trial Path commencing 2H26 Rapid enrollment & U.S.-sourced MVA vaccine against Clinical material successfully trial completion Mpox & Smallpox; will expand global manufactured and rea
Slide 14: GEO-MVA Mpox & Smallpox
\ pe e 4 > ~ @”-i GEO-MVA Mpox & Smallpox
Slide 15: Mpox Is Becoming a Persistent Global Threat — Vaccine Supply Is Far-Short of Need
Mpox Is Becoming a Persistent Global Threat — Vaccine Supply Is Far-Short of Need Disease Is Escalating Vaccination Is Essential Manufacturing Is the but Constrained Bottleneck •Multiple Mpox variants now circulating globally •Vaccination remains the •Reliance on a single primary tool for outbreak c
Slide 16: Mpox is a Life-Threatening Illness with Multiple Symptoms
Mpox is a Life-Threatening Illness with Multiple Symptoms Symptoms • Fever • Intense Headache • Muscle Aches • Back Pain • Low Energy • Swollen Lymph Nodes • Skin Rask/Lesions 16
Slide 17: GEO-MVA, the First U.S.-sourced MVA-Vaccine Against Mpox & Smallpox
GEO-MVA, the First U.S.-sourced MVA-Vaccine Against Mpox & Smallpox Current Landscape Strong Global Mandates GEO-MVA Entering Pivotal • Single global supplier (MVA- • High priority to establish a U.S.- Phase 3 Immunobridging BN) with limited production based supplier and eliminate Trial 2H26 capacit
Slide 18: Competitive Landscape
Competitive Landscape Bavarian Nordic (MVA-BN) GeoVax (GEO-MVA) Geography Non-U.S. U.S.-based Manufacturing Legacy CEF Continuous cell line Scalability Constrained Scalable Policy Risk High Aligned Supply Chain Fragile Sovereign 18
Slide 19: GEO-CM04S1 COVID-19
GEO-CM04S1 COVID-19 19
Slide 20: Unmet Need in Immunocompromised Patients Despite Widespread COVID-19 Vaccination
Unmet Need in Immunocompromised Patients Despite Widespread COVID-19 Vaccination GEO-CM04S1: A Differentiated, Limitations of Current Single- Multi-Antigen Approach Antigen COVID-19 Vaccines in •Co-expression of Spike (S) and Immunocompromised Populations Nucleocapsid (N) antigens •Reduced antibody
Slide 21: Critical Importance of Both Antibodies & T-cells for Protection Against COVID-19
Critical Importance of Both Antibodies & T-cells for Protection Against COVID-19 GEO-CM04S1 Immune Responses for Protection against S+N Proteins are Co-Expressed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nucleocapsid (N) Protein COVID-19 Disease Severity Asymptomatic Symptomatic S
Slide 22: Multiple Phase 2 Trials Demonstrate Strong T-cell Response to GEO-CM04S1
Multiple Phase 2 Trials Demonstrate Strong T-cell Response to GEO-CM04S1 in Immunocompromised Patients Immunocompromised/Stem Cell Immunocompromised/Chronic Transplant Patients Lymphocytic Leukemia (CLL) patients • Patients with hematologic malignancies • High at-risk population with abated antibody
Slide 23: Gedeptin Oncology
Gedeptin ® Oncology 23
Slide 24: Gedeptin: A Gene-Directed Enzyme Prodrug Therapy for Solid Tumors
Gedeptin®: A Gene-Directed Enzyme Prodrug Therapy for Solid Tumors Gedeptin® Platform Mechanistic Differentiation •Gene-directed enzyme prodrug therapy enabling •Converts a systemically administered prodrug localized tumor cell killing into a cytotoxic agent within the tumor •Intratumoral delivery m
Slide 25: Gedeptin Mechanism of Action
Gedeptin® Mechanism of Action Tumor-Targeted Prodrug Activated Gene Delivery Enzyme Expressed Cancer Cell Death + A therapeutic gene is Only in Tumor Inside Tumor Bystander Effect delivered directly into tumor Tumor cells begin A systemically administered prodrug is converted into a Activated drug k
Slide 26: Oncology – Next Steps
Oncology – Next Steps ▪ Advance Gedeptin® into Phase 2 in selected, needle-accessible solid tumors (initial focus: head & neck), leveraging orphan designation and prior safety/tumor-shrinkage data ▪ Initiate combination strategy development pairing Gedeptin® with ICIs to enhance inhibitor response ▪
Slide 27: Thank you!!
Thank you!! www.geovax.com 27